Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)

NCT01135615 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.

Interventions

DRUG: Sevelamer
DRUG: calcium acetate

Sponsor

Gulhane School of Medicine